Bexion Pharmaceuticals Announces the Addition of Dr. Raymond J. Tesi to Board of Directors

FOR IMMEDIATE RELEASE Covington, KY November 16, 2020               Bexion Pharmaceuticals, Inc. announced today that it has added RJ. Tesi, M.D. to its Board of Directors. Dr. Tesi has a distinguished career as a biotech entrepreneur and an experienced surgeon. Currently, he is President, Chief Executive Officer and acting Chief Medical Officer of INmune Bio (NASDAQ: ... Read More

Bexion Pharmaceuticals, Inc. Receives Rare Pediatric Disease Designation

FOR IMMEDIATE RELEASE [Covington, KY] September 30, 2020 Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that the Federal Drug Administration (FDA) has granted the company’s request for rare pediatric disease designation for BXQ-350, Bexion’s lead therapeutic, for the treatment of diffuse intrinsic pontine glioma (DIPG) and ... Read More

Bexion Pharmaceuticals, Inc. to Present Clinical and Pre-Clinical Data at 2020 SNO Annual Meeting

FOR IMMEDIATE RELEASE [Covington, KY: September 16, 2020] Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cures for cancer announced today it will present clinical and pre-clinical electronic posters with audio presentations at the Society of Neuro-Oncology (SNO) annual virtual conference to be held November 19-21, 2020. "We ... Read More

Bexion Pharmaceuticals Presenting BXQ-350 Data at ASCO 2020

For Immediate Release, Covington, KY May 13, 2020 Bexion Pharmaceuticals announced today that the following three abstracts submitted to the 2020 American Society of Clinical Oncology (ASCO) have been accepted for oral or poster presentation: Oral Presentation Tolerability and preliminary efficacy of BXQ-350 for refractory solid tumors and high-grade gliomas: First-in-human, first-in-class phase I trial. ... Read More

Bexion Pharmaceuticals Receives Orphan Drug Designation for BXQ-350 for Malignant Glioma from FDA

FOR IMMEDIATE RELEASE [Covington, KY May 6, 2020] Bexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for its proprietary drug, BXQ-350, for the treatment of malignant glioma, including diffuse intrinsic pontine glioma (DIPG). DIPG primarily affects children, with most diagnoses occurring between 5 ... Read More

Bexion Pharmaceuticals, Inc. To Present Clinical Data at 2019 NORD Annual Meeting

Clinical results support strong safety and tolerability for BXQ-350. Topline results support progression into Phase II studies. FOR IMMEDIATE RELEASE Covington, KY ~ 4 September 2019 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that it will feature a clinical poster presentation at the National Organization for ... Read More

Bexion Pharmaceuticals Announces the Opening of Phase I Part 3 First-in-Human Trial Using BXQ-350 for the Treatment of Cancer

FOR IMMEDIATE RELEASE Covington, KY ~ February 22, 2019 Bexion Pharmaceuticals, Inc. (Bexion) announced today the opening of Part 3 of their Phase I First-In-Human Trial using BXQ-350 for the treatment of cancer. This trial was designed to determine the maximum tolerated dose of BXQ-350 and to characterize its safety and pharmacokinetics. The Phase I ... Read More